{"result": "(\"entity\"<|>HOSPITAL VIRGEN DE LA VICTORIA<|>ORGANIZATION<|>Hospital Virgen de la Victoria is a clinical hospital specializing in endocrinology and clinical nutrition located in Málaga, Spain.)\n##\n(\"entity\"<|>HOSPITAL QUIRÓN-SALUD<|>ORGANIZATION<|>Hospital Quirón-salud is a clinical hospital specializing in endocrinology and clinical nutrition located in Málaga, Spain.)\n##\n(\"entity\"<|>JOSÉ MANUEL GARCÍA ALMEIDA<|>PERSON<|>José Manuel García Almeida is a specialist in endocrinology and clinical nutrition, serving as the head of the Endocrinology and Clinical Nutrition Service at Hospital Virgen de la Victoria.)\n##\n(\"entity\"<|>ANA M. GÓMEZ PÉREZ<|>PERSON<|>Ana M. Gómez Pérez is a specialist in endocrinology and clinical nutrition at Hospital Quirón-salud in Málaga.)\n##\n(\"entity\"<|>ROSARIO FERNÁNDEZ GARCÍA-SALAZAR<|>PERSON<|>Rosario Fernández García-Salazar is a specialist in endocrinology and clinical nutrition at Hospital Quirón-salud in Málaga.)\n##\n(\"entity\"<|>ENFERMEDAD CELIACA<|>EVENT<|>Celiac disease is a chronic inflammation of the small intestine mucosa triggered by gluten in genetically predisposed individuals, leading to malabsorption and various clinical manifestations.)\n##\n(\"relationship\"<|>JOSÉ MANUEL GARCÍA ALMEIDA<|>HOSPITAL VIRGEN DE LA VICTORIA<|>José Manuel García Almeida is the head of the Endocrinology and Clinical Nutrition Service at Hospital Virgen de la Victoria<|>9)\n##\n(\"relationship\"<|>ANA M. GÓMEZ PÉREZ<|>HOSPITAL QUIRÓN-SALUD<|>Ana M. Gómez Pérez is a specialist in endocrinology and clinical nutrition at Hospital Quirón-salud<|>8)\n##\n(\"relationship\"<|>ROSARIO FERNÁNDEZ GARCÍA-SALAZAR<|>HOSPITAL QUIRÓN-SALUD<|>Rosario Fernández García-Salazar is a specialist in endocrinology and clinical nutrition at Hospital Quirón-salud<|>8)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>JOSÉ MANUEL GARCÍA ALMEIDA<|>José Manuel García Almeida specializes in the treatment and management of celiac disease at Hospital Virgen de la Victoria<|>7)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>ANA M. GÓMEZ PÉREZ<|>Ana M. Gómez Pérez specializes in the treatment and management of celiac disease at Hospital Quirón-salud<|>7)\n##\n(\"relationship\"<|>ENFERMEDAD CELIACA<|>ROSARIO FERNÁNDEZ GARCÍA-SALAZAR<|>Rosario Fernández García-Salazar specializes in the treatment and management of celiac disease at Hospital Quirón-salud<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: MJ, Loyal S, Schwarze M, Lobers J, Selberg O, Ringe B, et al. Resting energy expenditure and nutritional state in patients with liver cirrhosis before and after liver transplantation. Clin Nutr 1994; 13:145-52.\n\n161. Osaki N, Ringe B, Gubernatis G, Takada Y, Yamaguchi T, Yamaoka Y, et al. Changes in energy substrates in relation to arterial ketone body ratio after human orthotopic liver transplantation. Surgery 1993; 113: 403-9.\n---\n# Tema 16. Soporte nutricional en la hepatopatía crónica y trasplante hepático 287\n\n162. Tsien C, Garber A, Narayanan A, Shah SN, Barnes D, Eghtesad B, Fung J, McCullough AJ, Dasarathy S. Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol 2014; 29: 1250-1257.\n\n163. Wagner D, Adunka C, Kniepeiss D, et al. Serum albumin, subjective global assessment, body mass index and the bioimpedance analysis in the assessment of malnutrition in patients up to 15 years after liver transplantation. Clin Transplant 2011; 25: E396-E400.\n\n164. García-Pajares F, Peñas-Herrero I, Sánchez-Ocaña R et al. Metabolic Syndrome After Liver Transplantation: Five-Year Prevalence and Risk Factors. Transplant Proc. 2016 Nov; 48(9):3010-3012.\n\n165. Hammad A, Kaido T, Uemoto S.Perioperative nutritional therapy in liver transplantation. Surg Today. 2015 Mar;45(3):271-83.\n---\nThe image appears to be a blank white page. There is no visible content, text, diagrams, or any other information present in this image. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\n# Tema 17.\n## Enfermedad celiaca. Dieta controlada en gluten\n\nJosé Manuel García Almeida\nEspecialista en Endocrinología y Nutrición Clínica. Hospital Virgen de la Victoria. Jefe del Servicio de\nEndocrinología y Nutrición Clínica. Hospital Quirón-salud. Málaga\n\nAna M. Gómez Pérez\nEspecialista en Endocrinología y Nutrición Clínica. Hospital Quirón-salud. Málaga\n\nRosario Fernández García-Salazar\nEspecialista en Endocrinología y Nutrición Clínica. Hospital Quirón-salud. Málaga\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 289-303.\n\n1. Introducción\n2. Manifestaciones clínicas de la enfermedad celiaca\n3. Manifestaciones nutricionales de la enfermedad celiaca\n4. Aproximación diagnóstica a la enfermedad celiaca\n5. Aproximación diagnóstica a la situación nutricional de la enfermedad celiaca\n6. Tratamiento dietoterápico\n7. Soporte nutricional artificial\n8. Resumen y conclusiones\n9. Bibliografía\n\n## 1. Introducción\n\n### 1.1. Introducción y epidemiología de la enfermedad celiaca\n\nLa enfermedad celiaca (EC), también conocida como «enteropatía sensible al gluten» o «esprúe no tropical», se define como una inflamación crónica de la mucosa del intestino delgado mediada inmunológicamente, en sujetos genéticamente predispuestos, que da lugar a un cuadro de malabsorción debido a la atrofia de las vellosidades intestinales y en la que la clínica mejora al hacer una dieta exenta de gluten y reaparece al reintroducir el gluten. La prevalencia en Europa es de 1:85-1:540¹, afectando principalmente a personas de raza blanca y en una relación 2:1 a favor del sexo femenino. La biopsia de intestino delgado es esencial para confirmar el diagnóstico. El tratamiento implica el asesoramiento dietético para suprimir las fuentes de gluten de la dieta y el seguimiento a largo plazo es importante por vigilar la aparición de complicaciones futuras\n\nLa EC es una intolerancia permanente al gluten, proteína que forma parte de algunos cereales de la dieta, capaz de provocar una lesión severa de la mucosa del intestino, cuyas manifestaciones clínicas pueden ser variadas. Esto solo ocurre cuando sujetos genéticamente predispuestos son expuestos al gluten de la dieta. La supresión del gluten mejora la sintomatología y normaliza la alteración intestinal, para volver a reaparecer cuando se reintroduce. Existe un amplio rango de manifestaciones clínicas, desde astenia en formas oligosintomáticas a síntomas intestinales floridos que incluyen diarrea severa, distensión y dolor abdominal. También cuando el trastorno persiste un largo\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}